Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Eli Lilly and Company .
Filed returns
51
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2026 | Eli Lilly and Company | Economic Development and Industry | EU and Irish life sciences policy development and competitiveness (Public policy or programme) | 9 | On lobbying.ie |
| May–Aug 2026 | Eli Lilly and Company | Education and Training | Research Funding for universities for PhD study in the area of STEM (Public policy or programme) | 3 | On lobbying.ie |
| Jan–Apr 2026 | Eli Lilly and Company | Health | Emerging trends in scientific research. (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2026 | Eli Lilly and Company | Health | Emerging trends in scientific research. (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2026 | Eli Lilly and Company | Economic Development and Industry | National Life Sciences Strategy (Public policy or programme) | 10 | On lobbying.ie |
| Sep–Dec 2025 | Eli Lilly and Company | Health | IPHA Framework Agreement for the Supply of Innovative Medicines. (Matters involving public funds) | 1 | On lobbying.ie |
| May–Aug 2025 | Eli Lilly and Company | EU Affairs | Advocate for improved EU policy environment to support continued investment in medicines innovation and manufacturing (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2025 | Eli Lilly and Company | Trade | Discuss the risks of potential tariffs on the complex global supply chains for innovative medicines (Public policy or programme) | 3 | On lobbying.ie |
| Jan–Apr 2025 | Eli Lilly and Company | EU Affairs | Highlight importance of maintaining EU competitiveness (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2025 | Eli Lilly and Company | EU Affairs | Advocate for improved EU Environment to support investment in medicines innovation and manufacturing (Public policy or programme) | 3 | On lobbying.ie |
| Sep–Dec 2024 | Eli Lilly and Company | Economic Development and Industry | Update on company operations in Ireland and EU (Public policy or programme) | 23 | On lobbying.ie |
| May–Aug 2024 | Eli Lilly and Company | Education and Training | Government funding for third level education programme in STEM (Matters involving public funds) | 1 | On lobbying.ie |
| May–Aug 2024 | Eli Lilly and Company | Economic Development and Industry | Investment and Economic Impact of Lilly Kinsale. (Public policy or programme) | 15 | On lobbying.ie |
| May–Aug 2024 | Eli Lilly and Company | Economic Development and Industry | Project Progress and Economic Impact of Lilly Limerick. (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2024 | Eli Lilly and Company | EU Affairs | EU Pharmaceutical Legislation (Legislation) | 11 | On lobbying.ie |
| May–Aug 2024 | Eli Lilly and Company | Economic Development and Industry | Project Progress and Economic Impact of Lilly Limerick. (Public policy or programme) | 4 | On lobbying.ie |
| May–Aug 2024 | Eli Lilly and Company | Economic Development and Industry | Project Progress and Economic Impact of Lilly Limerick. (Public policy or programme) | 11 | On lobbying.ie |
| Jan–Apr 2024 | Eli Lilly and Company | Economic Development and Industry | Project Progress and Economic Impact of Lilly Limerick. (Public policy or programme) | 52 | On lobbying.ie |
| Jan–Apr 2024 | Eli Lilly and Company | EU Affairs | EU Pharmaceutical Legislation (Legislation) | 2 | On lobbying.ie |
| Sep–Dec 2023 | Eli Lilly and Company | Economic Development and Industry | New Lilly manufacturing site in Limerick. (Public policy or programme) | 28 | On lobbying.ie |
| Sep–Dec 2023 | Eli Lilly and Company | EU Affairs | EU Pharmaceutical Legislation (Legislation) | 6 | On lobbying.ie |
| May–Aug 2023 | Eli Lilly and Company | Economic Development and Industry | Ireland and EU fiscal/economic policy and geopolitical environment. (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2023 | Eli Lilly and Company | EU Affairs | Introduction to Lilly Corporate, and company operations in Ireland (Public policy or programme) | 3 | On lobbying.ie |
| Jan–Apr 2023 | Eli Lilly and Company | Economic Development and Industry | Invitation to American Chamber Event (Public policy or programme) | 4 | On lobbying.ie |
| Jan–Apr 2023 | Eli Lilly and Company | Economic Development and Industry | Invitation to speak to global Board of Directors of Eli Lilly and Company about Ireland/EU Economic Policy & Environment (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2023 | Eli Lilly and Company | EU Affairs | EU Pharmaceutical Legislation (Legislation) | 1 | On lobbying.ie |
| Jan–Apr 2023 | Eli Lilly and Company | Economic Development and Industry | New Lilly manufacturing site in Limerick. (Public policy or programme) | 58 | On lobbying.ie |
| Jan–Apr 2023 | Eli Lilly and Company | Economic Development and Industry | Lilly Kinsale Development (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2022 | Eli Lilly and Company | Economic Development and Industry | New Lilly manufacturing site in Limerick. (Public policy or programme) | 51 | On lobbying.ie |
| Sep–Dec 2022 | Eli Lilly and Company | EU Affairs | EU Chemicals Strategy (Legislation) | 1 | On lobbying.ie |
| May–Aug 2022 | Eli Lilly and Company | Economic Development and Industry | Sustainable transport and environmental habitat protection efforts. (Public policy or programme) | 2 | On lobbying.ie |
| May–Aug 2022 | Eli Lilly and Company | Economic Development and Industry | Introduction to Lilly Corporate and Lilly operations in Ireland (Public policy or programme) | 4 | On lobbying.ie |
| May–Aug 2022 | Eli Lilly and Company | Economic Development and Industry | Update on Lilly operations in Ireland (Public policy or programme) | 2 | On lobbying.ie |
| May–Aug 2022 | Eli Lilly and Company | Economic Development and Industry | Update on Lilly operations in Ireland (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2022 | Eli Lilly and Company | EU Affairs | Updated EU Industrial Strategy (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2022 | Eli Lilly and Company | Economic Development and Industry | Introduction to Lilly Corporate and Lilly operations in Ireland (Public policy or programme) | 9 | On lobbying.ie |
| May–Aug 2021 | Eli Lilly and Company | Economic Development and Industry | EU Pharmaceutical Strategy (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2021 | Eli Lilly and Company | Economic Development and Industry | EU Pharmaceutical Strategy (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2021 | Eli Lilly and Company | Economic Development and Industry | EU Pharmaceutical Strategy (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2020 | Eli Lilly and Company | Economic Development and Industry | Update on Eli Lilly Kinsale manufacturing and supply chain operations during the pandemic to date (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2020 | Eli Lilly and Company | Health | Update on clinical research and product development carried out by Eli Lilly and Company with respect to treatments for Covid-19 (Public policy or programme) | 4 | On lobbying.ie |
| Jan–Apr 2020 | Eli Lilly and Company | Economic Development and Industry | Definition of "Essential Work" under the Covid-19 Regulations and Restrictions. (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2019 | Eli Lilly and Company | Transport | Discussions on safety and access improvements to roads around Lilly facilities in Kinsale and Little Island. (Matters involving public funds) | 3 | On lobbying.ie |
| Sep–Dec 2019 | Eli Lilly and Company | Economic Development and Industry | Update on Lilly's business in Ireland, the opportunities and challenges for the biopharma sector in Ireland in the comings years - incl BREXIT; the need for investment in STEM education at all levels of the education… (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2018 | Eli Lilly and Company | Economic Development and Industry | Update on Lilly's business in Ireland, the opportunities and challenges facing the company and the pharma sector in the comings years - incl challenges of BREXIT; the need for investment in 3rd level and post-graduate… (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2017 | Eli Lilly and Company | Transport | Investment in roads & transport infrastructure in Cork (Matters involving public funds) | 2 | On lobbying.ie |
| May–Aug 2017 | Eli Lilly and Company | Economic Development and Industry | General update on Lilly's business in Ireland and Europe, the opportunities and challenges facing the company and the pharma sector in the next 5 years - incl challenges of BREXIT; the impact of European policy (across… (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2017 | Eli Lilly and Company | EU Affairs | EU Regulation REACh - Registration, Evaluation, Authorisation and Restriction of Chemicals (Legislation) | 2 | On lobbying.ie |
| Jan–Apr 2017 | Eli Lilly and Company | EU Affairs | EU Regulation REACh - Registration, Evaluation, Authorisation and Restriction of Chemicals (Legislation) | 3 | On lobbying.ie |
| Jan–Apr 2016 | Eli Lilly and Company | Economic Development and Industry | Dr Lechleiter briefed Mr Martin on Lilly's most recent investments in Ireland. The economic recovery was discussed as well as the current business environment generally for FDI in Ireland as it relates to companies such… (Public policy or programme) | 1 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Economic Development and Industry | 30 | 58.8% | |
| EU Affairs | 12 | 23.5% | |
| Health | 4 | 7.8% | |
| Education and Training | 2 | 3.9% | |
| Transport | 2 | 3.9% | |
| Trade | 1 | 2.0% |